CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Hematology (ASH) Annual Meeting. Dr Mohamad Mohty, Head of Haematology and and celular therapy department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarises for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASH.
[embedyt] https://www.youtube.com/watch?v=11h4-PCDreU&width=550&height=309&iv_load_policy=3¢ervid=1&rel=0&showinfo=0[/embedyt]
